Quzyttir (Cetirizine HCl) Patent Expiration, LOE Window & CMS Spending

Quzyttir (Cetirizine HCl) by Esteve Sa: FDA Orange Book LOE 2030-02-28, 0 AB generics, $638K 2024 CMS Part D & Medicaid spend, and 6 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorEsteve Sa
FDA Application & PathwayN211415 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2030-02-28
Orange Book Patents (*PED Extensions)5 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$638K
2024 Medicare Part D Spend$638K
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)6 WAC filings (max 25.2% 2-yr change)